Calcitonin Gene-Related Peptide Antagonists in the Treatment of Episodic Migraine.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
08
10
2018
accepted:
30
11
2018
pubmed:
17
1
2019
medline:
8
2
2020
entrez:
17
1
2019
Statut:
ppublish
Résumé
Migraine is a prevalent, disabling neurological disorder involving the trigeminovascular system. Previous treatments were either originally intended for other conditions and/or associated with intolerable adverse effects (AEs). Calcitonin gene-related peptide (CGRP) is the most prevalent neuropeptide in the trigeminal afferent neurons and plays a significant role in pain sensitization central to migraine. The CGRP antagonists (gepants and monoclonal antibodies) are the first treatments created specifically for migraine, modulating pain signaling pathways and alleviating migraine attacks and recurrences. With their efficacy in several clinical trials and relatively fewer AEs, the CGRP antagonists show great promise for use in episodic migraine.
Substances chimiques
Antibodies, Monoclonal
0
Calcitonin Gene-Related Peptide Receptor Antagonists
0
Dipeptides
0
Piperazines
0
Quinazolines
0
Calcitonin Gene-Related Peptide
JHB2QIZ69Z
olcegepant
WOA5J8TX6M
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1121-1129Informations de copyright
© 2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics.